Andrea M Griesinger
Overview
Explore the profile of Andrea M Griesinger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
888
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
de Sousa G, Calzadilla A, Grimaldo E, Donson A, Sobral L, Jones K, et al.
Neuro Oncol
. 2025 Feb;
PMID: 39901723
Background: Posterior fossa molecular subtype A (PFA) ependymoma occurs in young children and is the deadliest subtype of pediatric ependymoma. High-risk subtypes with chromosome 1q+ and/or 6q- exhibit significantly poorer...
2.
Zahedi S, Riemondy K, Griesinger A, Donson A, Fu R, Crespo M, et al.
bioRxiv
. 2024 Apr;
PMID: 38645202
Key Points: There is a developmental hierarchy in neoplastic population comprising of both progenitor-like and mature cell types in both PA and GG.A more immunogenic, immune activating myeloid population is...
3.
Griesinger A, Calzadilla A, Grimaldo E, Donson A, Amani V, Pierce A, et al.
Clin Cancer Res
. 2024 Feb;
30(8):1544-1554.
PMID: 38334950
Purpose: There are no effective treatment strategies for children with highest-risk posterior fossa group A ependymoma (PFA). Chromosome 1q gains (1q+) are present in approximately 25% of newly diagnosed PFA...
4.
DeSisto J, Donson A, Griesinger A, Fu R, Riemondy K, Mulcahy Levy J, et al.
Neuro Oncol
. 2023 Nov;
26(3):538-552.
PMID: 37934854
Background: Pediatric high-grade gliomas (PHGG) are aggressive brain tumors with 5-year survival rates ranging from <2% to 20% depending upon subtype. PHGG presents differently from patient to patient and is...
5.
Grob S, Miller K, Sanford B, Donson A, Jones K, Griesinger A, et al.
J Neurooncol
. 2023 Oct;
165(1):161-169.
PMID: 37878192
Background: Neurocognitive deficits are common in pediatric brain tumor survivors. The use of single nucleotide polymorphism (SNP) analysis in DNA repair genes may identify children treated with radiation therapy for...
6.
Amani V, Riemondy K, Fu R, Griesinger A, Grimaldo E, de Sousa G, et al.
Acta Neuropathol Commun
. 2023 Sep;
11(1):158.
PMID: 37770931
Plexiform neurofibroma (PN) is a leading cause of morbidity in children with the genetic condition Neurofibromatosis Type 1 (NF1), often disfiguring or threatening vital structures. During formation of PN, a...
7.
Griesinger A, Riemondy K, Eswaran N, Donson A, Willard N, Prince E, et al.
iScience
. 2023 Sep;
26(9):107585.
PMID: 37694144
Ependymoma (EPN) is a devastating childhood brain tumor. Single-cell analyses have illustrated the cellular heterogeneity of EPN tumors, identifying multiple neoplastic cell states including a mesenchymal-differentiated subpopulation which characterizes the...
8.
Grob S, Miller K, Sanford B, Donson A, Jones K, Griesinger A, et al.
Res Sq
. 2023 Aug;
PMID: 37609195
Purpose: Neurocognitive deficits are common in pediatric brain tumor survivors. The use of single nucleotide polymorphism (SNP) analysis in DNA repair genes may identify children treated with radiation therapy for...
9.
Donson A, Bertrand K, Riemondy K, Gao D, Zhuang Y, Sanford B, et al.
Neuro Oncol
. 2023 May;
25(10):1854-1867.
PMID: 37246777
Background: Ependymoma (EPN) posterior fossa group A (PFA) has the highest rate of recurrence and the worst prognosis of all EPN molecular groups. At relapse, it is typically incurable even...
10.
Crotty E, Wilson A, Davidson T, Tahiri S, Gust J, Griesinger A, et al.
Curr Oncol Rep
. 2023 May;
25(8):847-855.
PMID: 37160547
Purpose Of Review: Correlative studies should leverage clinical trial frameworks to conduct biospecimen analyses that provide insight into the bioactivity of the intervention and facilitate iteration toward future trials that...